Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2
The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.
Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.
Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1
For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.
Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.
. Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.
Suma Kumar,Guy's and St Thomas' NHS Foundation Trust, London, UK Richard Leach,Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Case History A 68-year-old man presented with a four-week history of left-sided, dull, aching chest pain. He had known ischaemic heart disease, previous coronary artery bypass grafting, chronic obstructive pulmonary disease and treated duodenal ulceration.
Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Case History A 24-year-old woman was seen in the chest clinic with an eight-week history of cough with occasional sputum, fever and malaise. She also described an occasional nagging pain under her sternum and palpitations.
Would you trust a doctor to decide if you are an appropriate subject for assisted dying? I wouldn't, neither should you, and my colleagues who are not fortunate enough to be retired will be crazy if they allow themselves to be dragged into the process. Proponents of legislative change should man up and face the implications of their proposals, without hiding behind the medical profession.
Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as ...
The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this..
... guidelines document to assist medical professionals assess the evidence-based management of prostate cancer (PCa). The multidisciplinary guidelines panel includes urologists, radiation oncologists, a medical oncologist, a radiologist and a pathologist.
Learning outcomes: 1) Recognize who is at risk of prostate cancer; 2) Review the current recommendations on prostate cancer screening; 3) Recognize the harms associated with prostate cancer biopsy; 4)...
The study will shed additional light on the impact of Vectibix® under the current, standard clinical conditions of mCRC treatment in Greece. It will provide data on the duration and the outcomes of Vectibix® treatment in real-life setting.